Results 151 to 160 of about 4,548,713 (378)
The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu +10 morewiley +1 more sourceSystematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow +10 morewiley +1 more sourceMolecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom +8 morewiley +1 more sourcePATHOLOGY [PDF]
Neuro-Oncology, 1992 J.-i. Adachi, K. Totake, M. Shirahata, K. Mishima, T. Suzuki, T. Yanagisawa, K. Fukuoka, R. Nishikawa, A. Arimappamagan, N. Manoj, A. Mahadevan, D. Bhat, H. Arvinda, B. Indiradevi, S. Somanna, B. Chandramouli, S. A. Petterson, S. K. Hermansen, R. H. Dahlrot, S. Hansen, B. W. Kristensen, F. Carvalho, S. Jalali, S. Singh, S. Croul, K. Aldape, G. Zadeh, J. Choi, S.-H. Park, S. K. Khang, Y.-L. Suh, S. P. Kim, Y. S. Lee, S. H. Kim, S. Coberly, K. Samayoa, Y. Liu, P. Kiaei, J. Hill, S. Patterson, M. Damore, S. Dahiya, R. Emnett, J. Phillips, D. Haydon, J. Leonard, A. Perry, D. Gutmann, S. Epari, S. Ahmed, M. Gurav, S. Raikar, A. Moiyadi, P. Shetty, T. Gupta, R. Jalali, J. Georges, A. Zehri, E. Carlson, N. Martirosyan, A. Elhadi, J. Nichols, L. Ighaffari, J. Eschbacher, B. Feuerstein, T. Anderson, M. Preul, K. Jensen, P. Nakaji, H. Girardi, F. Monville, S. Carpentier, M. Giry, J. Voss, R. Jenkins, B. Boisselier, V. Frayssinet, C. Poggionovo, A. Catteau, K. Mokhtari, M. Sanson, H. Peyro-Saint-Paul, C. Giannini, T. Hide, H. Nakamura, K. Makino, S. Yano, S. Anai, N. Shinojima, J.-i. Kuroda, T. Takezaki, J.-i. Kuratsu, F. Higuchi, H. Matsuda, K. Iwata, K. Ueki, P. Kim, J. Kong, L. Cooper, F. Wang, J. Gao, G. Teodoro, L. Scarpace, T. Mikkelsen, M. Schniederjan, C. Moreno, J. Saltz, D. Brat, U. Cho, Y.-K. Hong, Y. S. Lee, R. Lober, L. Lu, M. H. Gephart, P. Fisher, M. Miyazaki, H. Nishihara, T. Itoh, M. Kato, S. Fujimoto, T. Kimura, M. Tanino, S. Tanaka, N. Nguyen, G. Moes, J. L. Villano, H. Nishihara, H. Kanno, Y. Kato, S. Tanaka, T. Ohnishi, H. Harada, S. Ohue, S. Kouno, A. Inoue, D. Yamashita, S. Okamoto, M. Nitta, Y. Muragaki, T. Maruyama, T. Sawada, T. Komori, T. Saito, Y. Okada, S. B. Omay, J. M. Gunel, V. E. Clark, J. Li, E. Z. E. Omay, A. Serin, L. E. Kolb, R. M. Hebert, K. Bilguvar, K. Ozduman, M. N. Pamir, T. Kilic, J. Baehring, J. M. Piepmeier, C. W. Brennan, J. Huse, P. H. Gutin, K. Yasuno, A. Vortmeyer, M. Gunel, A. Perry, S. Pugh, C. L. Rogers, D. Brachman, W. McMillan, J. Jenrette, I. Barani, D. Shrieve, A. Sloan, M. Mehta, A. Prabowo, A. Iyer, T. Veersema, J. Anink, A. S.-v. Meeteren, W. Spliet, P. van Rijen, T. Ferrier, D. Capper, M. Thom, E. Aronica, T. Chharchhodawala, M. Sable, M. C. Sharma, C. Sarkar, V. Suri, M. Singh, V. Santosh, B. Thota, M. Srividya, K. Sravani, S. Shwetha, A. Arivazhagan, K. Thennarasu, B. Chandramouli, A. Hegde +199 moreopenaire +2 more sourcesLoss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment
Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...Jin Gu Cho, Yubin Hah, Eunsik Yun, Hye In Ka, Aram Lee, Sora Han, Dawn Lee, Sung Wook Kim, Jong Hoon Park, Byung Su Kwon, Young Yang, Jongmin Kim +11 morewiley +1 more sourceGenomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text
Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton +19 morewiley +1 more source
